HIF1A and cancer: NNAs modifiedwith clinically validated antisense oligonucleotides (ASOs) that targethypoxia inducible factor 1-α (HIF-1-α) mRNA showed enhancedactivity compared with that of the soluble DNA across multiple celllines as well as a 3D cancer spheroid model.